Repligen RGEN Royalty — Revenue (Gross)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Repligen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Repligen's royalty — revenue (gross).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Repligen's royalty — revenue (gross)?
- Repligen (RGEN) reported royalty — revenue (gross) of $44K in Q1 2026.
- How has Repligen's royalty — revenue (gross) changed year-over-year?
- Repligen's royalty — revenue (gross) increased by 25.7% year-over-year, from $35K to $44K.
- What is the long-term trend for Repligen's royalty — revenue (gross)?
- Over 4 years (2021 to 2025), Repligen's royalty — revenue (gross) has grown at a 8.3% compound annual growth rate (CAGR), from $215K to $296K.
- What does royalty — revenue (gross) mean?
- This metric represents the total gross revenue generated from licensing intellectual property or proprietary bioprocessing technologies to third-party partners. It reflects the income streams derived from the commercialization of the company's patented innovations within the biopharmaceutical manufacturing ecosystem. Monitoring this figure helps investors assess the long-term value and market adoption of the company's technology portfolio independent of direct product sales.